93 related articles for article (PubMed ID: 23941577)
21. Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole.
Kyvernitakis I; Knöll D; Struck M; Hars O; Bauer T; Hadji P
J Cancer Res Clin Oncol; 2014 Jan; 140(1):159-66. PubMed ID: 24292402
[TBL] [Abstract][Full Text] [Related]
22. [Neoadjuvant endocrine therapy for postmenopausal estrogen receptor-positive patients with breast cancer].
Zhang B
Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):241-4. PubMed ID: 21575491
[No Abstract] [Full Text] [Related]
23. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
Winer EP; Hudis C; Burstein HJ; Wolff AC; Pritchard KI; Ingle JN; Chlebowski RT; Gelber R; Edge SB; Gralow J; Cobleigh MA; Mamounas EP; Goldstein LJ; Whelan TJ; Powles TJ; Bryant J; Perkins C; Perotti J; Braun S; Langer AS; Browman GP; Somerfield MR
J Clin Oncol; 2005 Jan; 23(3):619-29. PubMed ID: 15545664
[TBL] [Abstract][Full Text] [Related]
24. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Goss PE
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
[TBL] [Abstract][Full Text] [Related]
25. Remission of macroglobulinemia during anastrozole treatment for breast cancer.
Chettle C; Baker MA
N Engl J Med; 2005 Apr; 352(16):1725-6. PubMed ID: 15843681
[No Abstract] [Full Text] [Related]
26. The FACE trial: letrozole or anastrozole as initial adjuvant therapy?
Jonat W; Mundhenke C
Cancer Invest; 2007 Feb; 25(1):14-8. PubMed ID: 17364552
[TBL] [Abstract][Full Text] [Related]
27. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
28. Anastrozole for breast cancer: recent advances and ongoing challenges.
Buzdar AU
Expert Rev Anticancer Ther; 2006 Jun; 6(6):839-48. PubMed ID: 16761927
[TBL] [Abstract][Full Text] [Related]
29. Overcoming recurrence risk: extended adjuvant endocrine therapy.
Cianfrocca M
Clin Breast Cancer; 2008 Dec; 8(6):493-500. PubMed ID: 19073503
[TBL] [Abstract][Full Text] [Related]
30. Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.
Nabholtz JM
Oncology; 2006; 70(1):1-12. PubMed ID: 16439860
[TBL] [Abstract][Full Text] [Related]
31. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
[TBL] [Abstract][Full Text] [Related]
32. Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole.
Van Calster B; Van Ginderachter J; Vlasselaer J; Van de Putte G; Berteloot P; Timmerman D; Depypere H; Blomme C; Vlaemynck G; De Jonge E; Van den Broecke R; Vergote I; Amant F; Van Huffel S; Neven P
Menopause; 2011 Feb; 18(2):224-9. PubMed ID: 20881891
[TBL] [Abstract][Full Text] [Related]
33. Myocardial infarction due to coronary thrombus formation in a postmenopausal woman with breast cancer after initiation of letrozol therapy.
Canpolat U; Sunman H; Kaya EB; Aytemir K; Oto A
Int J Cardiol; 2012 Sep; 160(1):e1-2. PubMed ID: 22245476
[No Abstract] [Full Text] [Related]
34. [Aromatase inhibitors in the treatment of breast cancer: current status and some problems].
Song ST; Jiang ZF
Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):510-2. PubMed ID: 16188157
[No Abstract] [Full Text] [Related]
35. Body mass index and aromatase inhibitors: a step forward in individualizing therapy for breast cancer patients?
Słowik A; Frączek PA; Krzemieniecki K
Expert Rev Anticancer Ther; 2016 Jul; 16(7):759-66. PubMed ID: 27196669
[TBL] [Abstract][Full Text] [Related]
36. Psychometric analysis of the Patient Assessment of Own Functioning Inventory in women with breast cancer.
Bell MJ; Terhorst L; Bender CM
J Nurs Meas; 2013; 21(2):320-34. PubMed ID: 24053059
[TBL] [Abstract][Full Text] [Related]
37. [Development of overweight and obesity in breast cancer patients and its significance for diagnosis and clinical management: results of the Basel Breast Cancer Database 1990-2009].
Güth U; Schmid S; Eichholzer M
Praxis (Bern 1994); 2013 Apr; 102(8):473-80. PubMed ID: 23570924
[TBL] [Abstract][Full Text] [Related]
38. Intravenous leiomyomatosis treated with aromatase inhibitor therapy.
Biri A; Korucuoglu U; Zumrutbas N; Tiras B; Guner H
Int J Gynaecol Obstet; 2008 Jun; 101(3):299-300. PubMed ID: 18280477
[No Abstract] [Full Text] [Related]
39. Overweight, obesity, diabetes, and risk of breast cancer: interlocking pieces of the puzzle.
La Vecchia C; Giordano SH; Hortobagyi GN; Chabner B
Oncologist; 2011; 16(6):726-9. PubMed ID: 21632448
[TBL] [Abstract][Full Text] [Related]
40. [Management of aromatase inhibitor-related bone health in postmenopausal patients with early breast cancer: Chinese expert consensus].
Chinese expert consensus group for multidisciplinary management of bone health of breast cancerendocrine therapy
Zhonghua Zhong Liu Za Zhi; 2015 Jul; 37(7):554-8. PubMed ID: 26463336
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
